Market Spotlight: Sickle Cell Anemia
Market Spotlight: Sickle Cell Anemia
$1,318.00
This Market Spotlight report covers the Sickle Cell Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Sickle Cell Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.
Key Takeaways
- Using an estimated global prevalence of 0.04%, Datamonitor Healthcare approximated that there were 3.3 million prevalent cases of sickle cell anemia worldwide in 2019. Africa is estimated to account for 85% of worldwide cases.
- The approved drugs in the sickle cell anemia space target selectins, fetal hemoglobin, nicotinamide adenine dinucleotide, and hemoglobin. These drugs are administered via the oral route, except for Adakveo, which is available as an intravenous formulation.
- The majority of industry-sponsored drugs in active clinical development for sickle cell anemia are in Phase I. Therapies in development for sickle cell anemia focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral and subcutaneous formulations.
- High-impact upcoming events for drugs in the sickle cell anemia space comprise topline Phase IIb trial results for IMR-687 and topline Phase III trial results for Brilinta.
- The overall likelihood of approval of a Phase I hematology asset is 25.9%, and the average probability a drug advances from Phase III is 74.8%. Drugs, on average, take 9.3 years from Phase I to approval in the overall hematology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for sickle cell anemia have been in the early and mid-phases of development, with 79% of trials in Phase I–II, and only 21% in Phase III–IV.
- The US has a substantial lead in the number of sickle cell anemia clinical trials globally. The UK leads the major European markets, while Lebanon has the top spot in Asia.
- Clinical trial activity in the sickle cell anemia space is dominated by completed trials. Global Blood Therapeutics has the highest number of completed clinical trials for sickle cell anemia, with 10 trials.
- Global Blood Therapeutics leads industry sponsors with the highest overall number of clinical trials for sickle cell anemia, followed by Novartis
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Bone marrow transplantation
9 Hydroxyurea
9 Blood transfusions
10 Prophylactic therapy
10 Pain management
11 EPIDEMIOLOGY
12 MARKETED DRUGS
14 PIPELINE DRUGS
20 RECENT EVENTS AND ANALYST OPINION
20 IMR-687 for Sickle Cell Anemia (June 12, 2020)
21 IMR-687 for Sickle Cell Anemia (February 14, 2020)
23 CTX001 for Sickle Cell Anemia (November 19, 2019)
24 Rivipansel for Sickle Cell Anemia (August 2, 2019)
27 KEY UPCOMING EVENTS
28 KEY REGULATORY EVENTS
28 Global Blood Therapeutics’ Oxbryta Approved Broadly For Sickle Cell Disease
28 FDA Approval For Novartis’s Sickle Cell Treatment Adakveo
29 PROBABILITY OF SUCCESS
30 LICENSING AND ASSET ACQUISITION DEALS
30 Pfizer Ends Pact With GlycoMimetics After SCD Failure
30 Global Blood Partners With Syros For Sickle Cell, Beta Thalassemia Therapies
30 Vertex Partners With Molecular Templates To Enhance Stem Cell Candidates
31 CLINICAL TRIAL LANDSCAPE
32 Sponsors by status
33 Sponsors by phase
34 Recent events
35 BIBLIOGRAPHY
35 Prescription information
37 APPENDIX
LIST OF FIGURES
14 Figure 1: Overview of pipeline drugs for sickle cell anemia in the US
14 Figure 2: Pipeline drugs for sickle cell anemia, by company
15 Figure 3: Pipeline drugs for sickle cell anemia, by drug type
15 Figure 4: Pipeline drugs for sickle cell anemia, by classification
21 Figure 5: IMR-687 for Sickle Cell Anemia (June 12, 2020): Phase IIa – IMR-SCD-102
23 Figure 6: IMR-687 for Sickle Cell Anemia (February 14, 2020): Phase IIa – IMR-SCD-102
26 Figure 7: Rivipansel for Sickle Cell Anemia (August 2, 2019): Phase III – RESET
27 Figure 8: Key upcoming events in sickle cell anemia
29 Figure 9: Probability of success in the hematology pipeline
31 Figure 10: Clinical trials in sickle cell anemia
31 Figure 11: Top 10 drugs for clinical trials in sickle cell anemia
32 Figure 12: Top 10 companies for clinical trials in sickle cell anemia
32 Figure 13: Trial locations in sickle cell anemia
33 Figure 14: Sickle cell anemia trials status
34 Figure 15: Sickle cell anemia trial sponsors, by phase
LIST OF TABLES
13 Table 1: Marketed drugs for sickle cell anemia
16 Table 2: Pipeline drugs for sickle cell anemia in the US
20 Table 3: IMR-687 for Sickle Cell Anemia (June 12, 2020)
21 Table 4: IMR-687 for Sickle Cell Anemia (February 14, 2020)
23 Table 5: CTX001 for Sickle Cell Anemia (November 19, 2019)
25 Table 6: Rivipansel for Sickle Cell Anemia (August 2, 2019)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Melanoma KOL Interview – US 
Sign up to the